Microbot Medical announced its agreement with Brigham and Women’s Hospital to serve as one of the sites to perform the pivotal human clinical trial for its LIBERTY Endovascular Robotic Surgical System, as part of its Investigational Device Exemption application. This development, previously announced on June 17, 2024, follows the U.S. Food and Drug Administration’s approval to commence Microbot’s pivotal human clinical trial. The Company has completed the Site Initiation Visit, during which BWH clinical staff was trained on the clinical study protocols and the use of the LIBERT Endovascular Robotic Surgical System. In addition, the first shipment of LIBERTY investigational systems arrived at BWH this week in support of the clinical trial. Dr. Dmitry Rabkin, MD, PhD will lead the study for the site as principal investigator at BWH. The Company is in the process of engaging additional leading centers to participate in the clinical trial.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBOT:
- Microbot Medical Advances with New Clinical Trial Site
- Microbot Medical announces BWH as site for human clinical trial
- Microbot Medical Announces Brigham and Women’s Hospital as a Site for its Pivotal Human Clinical Trial
- Microbot Medical files to sell 3.21M shares of common stock for holders
- Microbot Medical Announces Closing of $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules